| Pharmaceutical Information |
| Drug Name |
Vorapaxar sulfate |
| Drug ID |
BADD_D02368 |
| Description |
Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation. |
| Indications and Usage |
Vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). It is usually co-administered with acetylsalicylic acid (ASA) and/or clopidogrel, and should therefore be administered as an addition to these medications as it has not been studied alone. |
| Marketing Status |
Prescription |
| ATC Code |
B01AC26 |
| DrugBank ID |
DB09030
|
| KEGG ID |
D09766
|
| MeSH ID |
C530299
|
| PubChem ID |
10077129
|
| TTD Drug ID |
D0VA0I
|
| NDC Product Code |
70347-208 |
| Synonyms |
vorapaxar | Zontivity | SCH 530348 | SCH530348 | SCH-530348 |
|
| Chemical Information |
| Molecular Formula |
C29H35FN2O8S |
| CAS Registry Number |
705260-08-8 |
| SMILES |
CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C.OS(=O)(=O)O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
